ars-pharma.com (SPRY) Company Sales Revenue

The GURU.Markets platform displays the corporate sales dynamics of ARS Pharmaceuticals (SPRY), where 0.12 represents the latest level value. The company's growth is driven by innovations in Neffy, a needle-free allergy spray. Demand for the drug is non-cyclical, although it depends on seasonal blooming. Patent protection and FDA approval create a powerful barrier to the emergence of generics.

ARS Corp (SPRY): Company Revenue from 04/28/2023 to 11/13/2026

Analytical breakdowns for ARS Pharmaceuticals, Inc. (SPRY)

- market price and analyst price targets:

Market Price ARS Corp|SPRY - Price Target Chart

- market capitalization details:

Market Value ARS Pharmaceuticals, Inc.|SPRY - Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share ARS Pharmaceuticals|SPRY - Company Book Value|Market Value to Book Value ars-pharma.com|SPRY - Aggregate Company Assets

- debt and solvency information:

Total Debt to Capital Coefficient ARS Pharmaceuticals|SPRY - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ARS Pharmaceuticals Inc|SPRY - Company Debts|Debts to Book Capitalization Ratio ARS Pharmaceuticals, Inc.|SPRY - Company Long-Term Debts|Company Short-Term Loans and Borrowings ARS Pharmaceuticals|Quick Ratio ars-pharma.com

- net income and valuation ratios data:

SPRY - Company Net Income|Expected Net Income ARS Pharmaceuticals|SPRY - Price to Earnings Ratio|Projected Price to Earnings ars-pharma.com|SPRY - PEG Multiple|EV/EBITDA Multiple ARS Pharmaceuticals, Inc.|SPRY - Operating profit EBITDA|Net earnings per share for the last 12 months ARS Pharmaceuticals|SPRY - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ars-pharma.com|SPRY - Net earnings per share growth this year|Earnings growth forecast for next year ARS Pharmaceuticals

- sales volume and revenue indicators:

SPRY - Company Sales|Company Projected Revenue Volume ARS Corp|SPRY - P/S Multiple|Market Cap to Expected Sales Ratio ARS Pharmaceuticals, Inc.

Comprehensive company analysis:ARS Corp (SPRY)

Manufactured product of ARS Pharmaceuticals Inc

Patent protection for ARS Pharmaceuticals (SPRY) nasal sprays and their integration into medical protocols minimize competition. The company's gross sales volume captures daily cash revenue from these products, stripping the data of market volatility. This indicator's trend reflects real market demand and the commercial efficiency of the business model. Steady growth in these metrics indicates high asset resilience, which reduces risk and justifies the long-term cost of capital.

Key competitors